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Over recent years it has become increasingly apparent that mucosal antibodies are not
only restricted to the IgM and IgA isotypes, but that also other isotypes and particularly
IgG can be found in significant quantities at some mucosal surfaces, such as in the gen-
ital tract. Their role is more complex than traditionally believed with, among other things,
the discovery of novel function of mucosal immunoglobulin receptors. A thorough knowl-
edge in the source and function and mucosal immunoglobulins is particularly important in
development of vaccines providing mucosal immunity, and also in the current climate of
microbicide development, to combat major world health issues such as HIV. We present
here a comprehensive review of human antibody mediated mucosal immunity.
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INTRODUCTION
Mucosal surfaces are the primary point of contact for numer-
ous infectious agents including the world’s three major causes
of mortality due to infectious disease, diarrheal diseases, lower
respiratory tract infections, and HIV/AIDS. According to WHO
statistics, together these account for 27.3% of global deaths. In
addition to defending from infection, the mucosal immune system
must be able to discriminate between pathogens and foreign pro-
teins derived from ingested material in order to prevent potentially
harmful responses to innocuous antigens.
Initial defense occurs through indiscriminate mechanical
action, mucus, cilia, and the epithelial cell barrier, for example. The
epithelial cells themselves provide these surfaces with bactericidal
proteins and antimicrobial peptides (1) and take a large part in
generating the cytokine milieu required for the adaptive immune
response, and probably participate directly in the initiation and
eradication of infection as discussed below. More specialized
action is directed and regulated by surveillant myeloid phagocytes
and the other cells of the mucosal immune system, located in local
lymphoid compartments which make up the mucosa-associated
lymphoid tissue (MALT) as well as in the lamina propria. Cel-
lular immunity has a clear role in induction and coordination
of the adaptive immune response at mucosal surfaces [reviewed
in (2)] but here we concentrate on the contribution of the end
product of the humoral immune response. This is characterized
by secretory IgA (SIgA) that is present at higher levels at mucosal
sites than other immunoglobulins, notable exceptions to this rule
being the female and male genital tract (3–5), bronchoalveolar
fluid, and bile (6) where IgG is dominant. Although present at
lower levels in external secretions [levels of all immunoglobu-
lins in mucosal secretions are reviewed by Norderhaug et al. and
Mestecky et al. (5, 7)], IgM also has a role in mucosal defense
and it has recently been noted that IgD may play an important
part (8).
It has been observed that macromolecules derived from plasma
can exude to the mucosal surface by bulk flow through epithe-
lial tight junctions that can filter these molecules depending on
size (∼7–15 Å) and sub-epithelial hydrostatic pressure (9, 10).
However, the different immunoglobulin isotypes (IgG ∼55Å),
are bigger than most of these tight junctions to allow for free
passage. They do however interact with novel immunoglobulin
receptor systems that mediate their functions via passive trans-
fer, active destruction through phagocytosis, or antigen sampling
and presentation for enhanced immune responses. Collectively,
these functions are crucial for the interplay between the innate
and adaptive immune systems. Current knowledge in this area
together with latest findings on how subversive pathogens evade
these mechanisms are reviewed below.
SOURCES AND PASSIVE FUNCTION OF MUCOSAL
IMMUNOGLOBULINS
IMMUNOGLOBULIN A
The mucosal environment is programed to induce B cell class
switching to IgA production as both mucosal T cells and mucosal
epithelial cells themselves produce TGF-β and IL-10, cytokines
essential for programing of committed IgA producing B cells (11).
Although, systemic IgA responses tend to occur in germinal cen-
ter reactions, and require T cells, a significant portion of the IgA
response (CD27−IgA+) does not require T cells, as they harbor
low frequency of somatic hypermutations and develop normally
in both mouse and humans lacking either CD40 or CD40L, respec-
tively (12, 13). In the gut, this T cell independent mechanism
preferentially leads to class switching to IgA2 with λ-light chains
(13, 14). The reason for the selective usage of the λ-locus for
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the light chains is unknown, but may reflect the selection for
binding to unknown human pathogens – a feature also found
for IgD responses in tonsils (8). Although serum IgA is mainly
monomeric, originating from the bone marrow, but also lymph
nodes and spleen, at mucosal surfaces it is usually polymeric, syn-
thesized locally by plasma cells located in the lamina propria (15).
These polymers, most often dimers, linked by the cysteine rich J
chain, are secreted across the mucosal epithelium via the polymeric
immunoglobulin receptor (pIgR, also termed membrane secretory
component, SC). Post transcytosis protease cleavage releases IgA
complexed with the extracellular part of the pIgR (bound SC), as
SIgA into the mucosal lumen (Figure 1A). SIgA has traditionally
FIGURE 1 |Transport of Immunoglobulins to mucosal surfaces. Mucosal
IgA, IgM, produced locally at the lamina propria, and IgG, produced either
locally or systemically, are transported by (A) the Polymeric Immunoglobulin
Receptor (pIgR) or (B) by the Neonatal Fc-Receptor (FcRn), respectively. (A)
The pIgR, expressed on serous-type secretory epithelial cells, specifically
binds J chain containing dimers (and larger polymers) of IgA or pentamers of
IgM at basolateral surfaces, but not serum-derived monomeric IgA (1). This
prompts uptake and transport through the cell (2), eventually resulting in
subsequent vesicle fusion at apical sites where the pIgR is cleaved, releasing
the extracellular domain of pIgR either as free SC (unoccupied) or bound SC in
SIgA and SIgM (3). SC remains bound to the IgA and IgM, for IgA covalently,
blocking its interaction with the FcαRI, but can also be released from IgM
upon purification. (B) Mucosal transport of IgG is initiated by pinocytosis
and/or receptor mediated uptake of IgG. During the initial stages of
IgG-transport, the pH is probably neutral, under conditions where FcRn has
no or negligible affinity for IgG (1). After acidification of the developing
vacuoles and fusion with FcRn-containing vesicles or tubules, changes in the
charge of the IgG-Fc tail induce the recognition of IgG by FcRn, where a
single IgG is probably recognized by two FcRn molecules on parallel
membranes (4). This induces the rescue of this IgG from lysosomal
degradation and transcytosis to the apical surface, where the cargo is
released at physiological pH (3). The relative transport rate for the IgG
subclasses is similar to what is seen for their FcRn-mediated half-life, with
few exceptions, as discussed in the text, and likely to be allotype dependent
for IgG3 (indicated with an asterix). Interaction of opsonized pathogens or
immune complexes may also cause local complement activation, eventually
leading to target lysis and/or opsonization, but also release of C5a, a powerful
anaphylatoxin and a chemo attractant. Interaction with myeloid FcγR and
FcαR also leads to degranulation and release of chemotactic factors, thereby
inducing enhanced migration of lymphoid and myeloid cells to the inflamed
site, here depicted above the surface, but in real life probably scavenging the
surface by close adherence (5), eventual clearance of the infection and
resolution of inflammation. As discussed in the text, these immunoglobulin
transport pathways may also neutralize pathogens localized either at the
basolateral side or within intracellular vacuoles allowing for their intracellular
degradation or expulsion. Also discussed in the text, is the possible
involvement of the cytoplasmic Ig-receptor TRIM21 for intracellular
degradation of opsonized non-enveloped viruses and intracellular bacteria.
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been perceived as an anti-inflammatory mediator (16) with three
major functions: (1) to physically block pathogen attachment and
invasion (immune exclusion), (2) to recognize foreign antigens
and escort them through epithelial cells ridding the mucosa of
excess antigens, and (3) to intercept viruses intracellularly (during
transcytosis), thereby facilitating their neutralization and expul-
sion already within infected cells (17). This latter mechanism was
suggested and experimentally confirmed in the early 90s and has
been reconfirmed for the measles virus (17, 18). Further support
for this view of SIgA as a non-inflammatory antibody comes from
its poor ability to activate the classical complement pathway; it
lacks the C1q binding motif found in IgG. Although it has been
shown to activate complement through the lectin pathway, this is
probably dependent on the glycosylation status of in the IgA1 (19).
IgA1 glycosylation has recently been shown to be highly complex,
with several glycosylation isomers (20, 21), suggesting that IgA-
function may also be modulated though glycosylation in a similar
manner as recently described for IgG as discussed below (22). Sur-
prisingly,glycosylation of the IgA-bound SC has also been reported
to affect binding of IgA to commensal bacteria (23). Importantly,
IgA can also actively mediate protection against invasive disease,
because, in addition to transport of secretory immunoglobulins,
the pIgR is able to transport immune complexes across polarized
cell lines in vitro, releasing them at the apical surface, hence sug-
gesting a direct role for the pIgR and IgA in clearance of pathogens
from the sub-epithelial mucosa (24).
IMMUNOGLOBULIN M
IgM is the first immunoglobulin to appear during an infection and
is found at detectable albeit low levels in secretions. The largest of
the antibodies, it occurs as a pentamer and is transported across
epithelial cells in the same way as IgA, via its J chain and the pIgR
(Figure 1A) (25). There are fewer IgM than IgA secreting cells at
mucosal surfaces, and its net-mucosal transfer is mediated less effi-
ciently than that of IgA (25). As pIgR-mediated epithelial transport
of both isotypes occurs at equal rates in vitro (5), the reason for the
lower transport is probably due to its large size and therefore less
efficient diffusion through epithelial basement membranes, result-
ing in a lower mucosal concentration than what could be predicted
from the local production of IgM. Despite these low mucosal levels,
it does show elevated levels in individuals with IgA deficiency, in a
compensatory manner, and provides some protection from infec-
tion. Although it hardly activates myeloid cells, mediating effector
functions primarily through complement, a potential role has
recently been described for the myeloid IgM receptor, TOSO (26).
Mice lacking this receptor show elevated Reactive Oxygen Species
(ROS) production after formyl-Methionyl-Leucyl-Phenylalanine
(fMLP) stimulation, but reduced IgM-mediated phagocytosis,
reduced inflammatory cytokine production after challenge with
Listeria monocytogenes, ultimately leading TOSO−/− mice to suc-
cumb faster to Listeria infection (27). The role of this receptor
in humans for IgM-mediated antimicrobial defense remains to be
elucidated.
IMMUNOGLOBULIN D
Monomeric IgD forms the major part of the B cell receptor and is
therefore present in membrane bound form on naïve and memory
IgM+IgD+ B cells and also on class switched IgM−IgD+ memory
B lymphocytes (8). IgD secreting plasmablasts are scarce in bone
marrow and the digestive system (28), but are found at higher
frequencies in the lacrimal gland, nasal mucosa, and tonsils (29),
with as many as 20–25% of plasmablasts/plasma cells producing
IgD being reported for the tonsils (8). The number of these cells has
however been disputed, and may be on average be below 5% (30).
Research concerning the function of IgD has lagged behind that of
other immunoglobulins, due in part to methodological difficul-
ties in detection, its low concentration in serum, and its absence
in a number of animal systems including rabbit and guinea pig
(31). However, human IgD class switched B cells, most of which
also express the λ-light chains as discussed above for IgA, have
recently been identified and shown to secrete both mono- and
poly-reactive antibodies which react with respiratory pathogens
including Haemophilus influenzae. It has been hypothesized to
be part of an evolutionarily conserved immune surveillance sys-
tem activating effector functions of basophils (8). Many questions
regarding the function of IgD, including how IgD finds its way
into secretions – which may occur by either receptor- or non-
receptor mediated mechanisms, remain unanswered [reviewed in
(32)], and await confirmation.
IMMUNOGLOBULIN G
The presence of IgG in external secretions has largely been
ignored in the literature, but recent work has demonstrated that
this isotype is capable of mediating active humoral protection
in various mucosal locations (33–36). Human IgG consist of
four subclasses, IgG1, IgG2, IgG3, and IgG4, with reference to
their decreasing abundance in serum. They all have remarkably
different effector functions, with respect to both complement
activation and binding to FcγR (as discussed in a more detail
below), with the general order of activating capacity for both being
IgG3> IgG1>> IgG2> IgG4. IgG is present at significant levels
at all mucosal surfaces, and although IgA is the most abundant
mucosal antibody, IgG concentrations actually exceed those of IgA
at a number of locations, including the male and female genital
tracts and bronchoalveolar fluids, where it is the predominant anti-
body isotype (3, 4). Mucosal IgG is believed to be produced locally
as IgG producing plasma cells are certainly found locally in the gen-
ital tracts of both sexes, but can also transudate from serum – the
level of which is under regulation by hormonal- and menstrual-
cycle in females (4, 37). Regardless of the source, IgG is probably
transported through all epithelial layers, under conditions when
the epithelial layer is intact with low sub-epithelial pressure, by the
neonatal Fc-receptor (FcRn), a MHC class I homolog (Figure 1B).
Parenteral administration of passive neutralizing IgG has been
shown to prevent oral rotavirus (36), oral and vaginal HIV-1 trans-
mission (34), and lung infection by Streptococcus pneumoniae (35).
The mechanisms of this protection may be different depending on
the site of action, but have been proposed to occur in secondary
lymphoid tissues, mediated by active phagocytosis. Pathogen clear-
ance may also involve complement (35) and it is possible that
strong activation of complement by IgG could cause inflammation
and damage to the epithelial barrier. Cross-linking of Fcγ receptors
also triggers a range of other effector functions including phago-
cytosis, respiratory burst, and Antibody Dependent Cell-mediated
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Cytotoxicity (ADCC) processes that release inflammatory media-
tors and may also cause damage to epithelial barriers in chronic
inflammation [reviewed in (38)]. The activity of the IgG response,
can be modified through addition and removal of glycan-moieties
at Asn297 in the Fc-portion [reviewed in (39)]. In particular core-
fucosylation, normally present is serum of>90% of all IgG, affects
the binding of all IgG subclasses to FcγRIIIa/b up to several orders
of magnitude with accompanying increases in cellular responses
(40). Importantly, this type of glycosylation can be regulated at
the level of the B cells in humans, as it can be found in certain
responses, e.g., anti-platelet responses seen in pregnancy (22). A
role for this type of regulation during mucosal immune responses
still needs to be investigated.
IgG subclass levels found at mucosal sites, with relative low IgG3
concentrations compared to plasma, correspond what is known
about half-life extension (long half-life of IgG1, IgG2, and IgG4,
but short half-life of IgG3) and transport though the placenta (no
active transport of IgA, but active transport of all IgG, of which
transport of IgG1, and IgG4 exceed that of the mother, but with
low transport of IgG3 and IgG2), both roles carried out by the
FcRn (41, 42). Mucosal transport of IgG subclasses therefore corre-
lates with their known half-life and placental-transport properties,
suggesting IgG to be actively transported across these mucosal sur-
faces by FcRn. For example, mucosal transport of IgG3, the only
IgG subclass with a half-life of only 1 week (compared to 3 weeks
for the other subclasses) seems invariably lower than for the other
subclasses (43). A potential concern is that it has been proposed
that the long hinge of IgG3 may be more susceptible for proteolytic
cleavage (33), but given that this effect is found, for example, in
seminal secretion and in saliva, which are quickly expelled, this
seems less likely (43). Transport of IgG2, with the exception of
salivary transport, seems to be reduced, mirroring what is seen for
placental-transport – where both IgG2 and IgG3 are transported to
a lesser degree than IgG1 and IgG4 (44). Although mucosal trans-
port of IgG3 was much reduced compared to the other subclasses
in the above mentioned study and others (43), we recently found
IgG3 is never the less very efficacious in protecting against lung
infection by S. pneumoniae (33). More importantly, the relative
abundance of mucosal IgG3 may also be increased in individuals
expressing the G3m(s,t) allotype of IgG3 (common in Asians).
This is because, unlike the G3m(b) or (g) allotypes (common in
Europeans) with an arginine at position 435, the G3m(s,t) allo-
type contains an histidine at this position. This results not only in
improved pH-dependent binding to FcRn and prolonged half-life,
but also increased placental-transport, suggesting mucosal trans-
port of this IgG3 allotype to be increased as well (33, 41). As
such, this allotype of IgG3 with both prolonged half-life and even
stronger effector functions than all the other IgG subclasses (both
in terms of complement activation and binding to FcγR), may
prove important in both health and inflammatory diseases at the
mucosa.
RECEPTORS AND ADAPTIVE IMMUNITY
There are two main, and subsequently well characterized IgA
receptors, the pIgR and FcαRI. Several other receptors have also
been reported to bind IgA with, as yet, unclear or uncharacterized
functions. The receptors for IgG can be classified into the
well-known FcγR family, consisting of several proteins expressed
on myeloid cells, and the FcRn that is ubiquitously expressed at
various levels in different cells. These and other less character-
ized immunoglobulin receptors are summarized in Table 1 and
discussed below.
POLYMERIC IMMUNOGLOBULIN RECEPTOR
The pIgR is responsible for the transport of both SIgA and IgM
from the basolateral to the apical epithelial surface at the mucosa
(Figure 1A). Irrespective of being bound by IgA or IgM, upon
the arrival of the pIgR at the apical surface, the extracellular SC
domain is cleaved and the remaining receptor degraded. The SC
remains attached to IgA and IgM, but for IgA the linkage is more
stable as it is covalent (45). Therefore free, soluble SC can be found
at the mucosal surface and each pIgR molecule can only mediate
one cycle of transport (46). As discussed below, the pIgR may also
recycle without cargo and without cleavage of the SC. Upregula-
tion of pIgR synthesis is mediated by several cytokines including
IFNγ, IL-1, and TGF-β, resulting in increased transport of IgA
across the epithelial layer (47, 48). Recently, secretion of IL-17
from Th17 cells was suggested to not only stimulate homing of
B cells to the lungs but also to upregulate pIgR expression and
enhanced secretion of IgA and IgM, a pathway which is usually
held in check by antigen-specific by regulatory T cells (49). Thus,
under inflammatory situations or general immunological imbal-
ance, the resulting Th17 like conditions may stimulate mucosal IgA
and IgM production and secretion, and intensify the response.
FcαRI
The other major IgA receptor is the FcαRI which is found consti-
tutively on cells of myeloid lineage although expression levels are
affected by cytokines and vary with cell type (50). The FcαRI is
found in association with the common FcR γ-signaling chain (also
found associated with FcγR) which has a cytoplasmic immunore-
ceptor tyrosine-based activation motif (ITAM) (51). The FcR
γ-chain is responsible for initiation of intracellular events and
effector functions, including inflammatory responses against IgA
opsonized pathogens. FcαRI activation status can be modulated
through protein phosphatase 2 (PP2A) dependent inside-out sig-
naling, whereby proximal inflammatory mediators may determine
whether or how FcαRI is spatially integrated into the lipid mem-
brane and therefore if FcαRI is capable of interacting strongly with
IgA to activate cellular responses (Figure 2A) (52). In contrast to
serum-derived monomeric IgA (mIgA),which can mediate a num-
ber of inflammatory effector functions through the FαRI including
endocytosis, phagocytosis, a particularly strong respiratory burst,
and ADCC (50, 53, 54), SIgA is unable to interact with FcαRI.
This interaction with the FcαRI is blocked by steric hindrance of
the bound SC, contributing to the anti-inflammatory role of IgA
at mucosal surfaces where SIgA accounts for the majority of IgA
present (50, 53–55).
FcγR
The major IgG receptors, FcγRs, are represented by three different
classes found on cells of myeloid origin. They activate myeloid
cells through the same ITAM-dependent FcRγ-signaling chain
(except for FcγRIIa and FcγRIIc that have their own cytoplasmic
ITAM-motives, and FcγRIIb with an immunoreceptor tyrosine-
based inhibitory motif, ITIM) upon receptor crosslinking. This
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Table 1 | Immunoglobulin receptors involved in transport and/or functions of effector cells or molecules at epithelial surfaces.
Receptor Ligand Cell type Characteristics
pIgR (102) J chain in the context of
IgA or IgM
Secretory epithelial cells Transports IgA/IgM across epithelial cell layer
FcαRI (53, 103) IgA1/2 (SIgA) Myeloid cells Major IgA receptor*
Fcα/µR (104) IgM> IgA B cells, macrophages Type I transmembrane protein, mediates B cell
endocytosis of antibody coated targets
FcµR/TOSO (26) IgM B- and T-cells Highly specific for IgM. Currently undetermined function
β-galactosyltransferase
(105)
pIgA, mIgA, SIgA Liver, myeloid, intestinal epithelial cells Unknown function, cation independent binding
Transferrin receptor
(CD71) (106)
mIgA1>pIgA Renal mesangial cells Unknown function, binding of IgA does not interfere with
transferrin binding
SC-receptor (107, 108) Secretory component Eosinophils, basophils Binding of IgA may cause degranulation
Asialoglycoprotein
receptor (ASPGR) (109)
Terminal galactose and
N -acetyl-d-galactosamine
residues
Liver, myeloid, epithelial cells Involved with IgA clearance from blood and liver
DC-SIGN (92, 94) IgA/IgG Sub-mucosal dendritic cells Possible involvement in immune surveillance at mucosal
surfaces, immune regulation
FcγRI IgG Monocytes, neutrophils, macrophages These are the three major IgG receptor classes. A
number of further isoforms have been described, of
which all, except FcγRIIb, mediate cellular activation
FcγRII IgG Monocytes, neutrophils, eosinophils,
basophils, B cells, platelets,
macrophages, langerhans cells,
endothelial cells of the placenta
Different functions are meditated on cross-linking by
ligand or specific antibody, including phagocytosis,
ADCC, cytokine release, superoxide production, and
antigen presentation, except for the FcγRIIb which
inhibits these ITAM-responses though its ITIM-signaling
encoded in its cytoplasmic tail (110, 111)
FcγRIII IgG Monocytes, neutrophils, eosinophils,
NK cells, T cells, macrophages, kidney
mesangial cells, placental trophoblasts
FcRL5 (and FcRL4) (112) IgG (FcRL4 only IgG3 and
IgG4)
B cells (FcRL4 on memory B cells) ITIM-containing inhibitory receptors, that probably
functions similar to FcγRIIb
TREM21 (98, 99) IgG, IgM, others? Mostly cells, high expression in
myeloid cells
Cytoplasmic receptor, prompting ubiquitination-depended
breakdown of IgG-opsonized particles
FcRn (64, 70, 72, 113) IgG Ubiquitous, high in epithelial cells,
placental syncytiotrophoblasts,
endothelial cells, monocytes, PMNs,
dendritic cells
Transplacental transport, transepithelial transport, IgG
regulation
FcδR (8) IgD Basophils, mast cells Cytokine inducible. Other, less defined receptors have
also been described on lymphocytes and basophils
(32, 114).
TRIM21 (99, 101) IgG, IgM, IgA All cells, high on immune and
endothelial cells
Intracellular Ig-receptor targeting cytoplasmic
Ig-complexes for ubiquitin-dependent proteasome
degradation
FcεRII (CD23) IgE B cells, enterocytes (90, 91) In the gut CD23 promotes bidirectional transport of IgE
and IgE complexes in the gut, thereby providing antigen
sampling mechanism, suggesting a role for food allergies,
and possibly protection against helminth infection
*A number of even less established receptors for IgA on mesangial-, M-, epithelial-, and T-cells have also been reported.
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FIGURE 2 | Activation of cellular responses through Fc-Receptors. (A)
The activity of FcαRI (left) is controlled through inside-out signaling through
PP2A, that dephosphorylates the intracellular tail of FcαRI, enabling binding
of IgA (58). Conversely, FcγR (right) seem to be continuously enabled,
although crystallographic data suggest a dimeric form may exist that cannot
interact with IgG without disrupting the inert FcγRIIa dimer (115). The
FcγRIIa engaged by IgG may however form a higher order dimer, or
multimer, with either another FcγR-IgG unit or unligated FcγR, forming an
active signaling complex after engagement with IgG-opsonized target.
However, without crosslinking of FcαRI through IgA and it’s cognate
antigen, the FcαRI has been reported to lead to down regulation of FcγRI
signaling through phosphorylated SYK (58). (B) Importantly, co-engagement
of FcγR and FcαR results in a strong activation of phagocyte responses,
with FcαRI leading to a more prominent respiratory burst activation, while
FcγR result more a prominent phagocytosis response (54). (C) FcγR can
also mediate inhibitory signal, because IgG-ligated, either by monomers at
high concentrations, dimers, or F(ab’)2-anti FcγR, can also cause inhibition
of other ITAM-, but also non-ITAM, depended cellular activation, also
through phosphorylated SYK (60).
results in similar effector functions as seen for the FcαRI that
can be down modulated through a negative feedback loop via
the inhibiting FcγRIIb [extensively reviewed elsewhere (56)]
(Table 1). The binding affinity to each of the FcγR differs markedly
between different IgG subclasses, the general consensus being
IgG3≥ IgG1> IgG2> IgG4, with few exceptions depending on
the FcγR. The most important exceptions from the rule are that
IgG2 only binds FcγRIIa, and preferentially the H131-FcγRIIa
allotype (also known as the low-responder form, based on its low
binding to mouse IgG1) and IgG4 binding FcγRI with considerable
high affinity. Remarkably, the affinity of the IgG subclasses are not
directly related with binding of myeloid cells to opsonized targets,
as IgG3 seems to surpass all other subclasses in this respect for all
FcγRs, with few exceptions (57).
CROSSTALK BETWEEN ACTIVATING FcR FAMILIES
In the absence of specific antigen recognized by mIgA, mIgA is
also able to mediate anti-inflammatory functions by interact-
ing with FcαRI at a low level in a monovalent fashion (without
crosslinking FcαRI) and impeding ITAM-initiated signaling of
FcγR, by recruitment and phosphorylation of SHP-1, probably
through the low level activation of SYK (58, 59) (Figure 2A). In
contrast, serum IgA invokes a massive activation of the myeloid
system when opsonized antigen-specific IgA is present (50, 53,
54) (Figure 2B). Thus IgA has several roles; while SIgA is gen-
erally anti-inflammatory, mIgA, through FcαRI, can either medi-
ate massive activation of the myeloid system (Figure 2B) or be
immunomodulatory (Figure 2A), depending on the presence or
absence of its cognate antigen.
Similar to the FcαR, FcγR, human FcγRIIIa can mediate
inhibitory responses of other cellular activation responses, includ-
ing fMLP, uptake endocytosis through the MARCO scavenging
receptor, but also other ITAM bearing receptor, like FcεRI (60)
(Figure 2C). A similar mechanism has been demonstrated in mice
for mouse FcγRIII (61). This inhibition also involves recruitment
of SHP-1, and its phosphorylation, probably through SYK. This
inhibition, both for FcγR and FcαRI, therefore seems to be a
general phenomenon of ITAM mediated signaling, that acquires
inhibitory ITAM signaling properties (ITAMi) with low level of
engagement through monomer or dimers, but activation prop-
erties only when fully cross linked (58–60). This pathway may
thereby explain at least partly the inhibitory effect of high-dose
Intravenous Immunoglobulin (IVIg) treatment in autoimmune
diseases. But what would be the physiological relevance of this
inhibitory mechanism, as most immune responses against invad-
ing pathogens result not only in either IgA or IgG responses, but
both? Perhaps the solution is to be sought by the fact that some
autoimmune responses seem to be mostly restricted to IgG, allow-
ing for dampening of these unwanted responses. If true, it may also
explain increased tendency of autoimmune diseases, for example
in IgA deficiency (62).
NEONATAL Fc-RECEPTOR
The neonatal Fc-receptor is responsible for the materno-fetal
transplacental-transport of IgG (63), and the extension of the
half-life of IgG and albumin (64). Originally, FcRn was described
in rodents to transport IgG from mothers milk to the suckling
neonates, providing them with humoral immunity after birth (65,
66). Later work utilizing electron tomography, has shown IgG to
be taken up by FcRn-positive epithelial cells in the proximal small
intestines, where it traverses the cell through entangled network of
tubular structures, through multivesicular bodies, accumulating
in basolateral intercellular spaces separated from the gut lumen by
tight junctions (67, 68). Initiation of transport, takes place after
binding of IgG and albumin by FcRn at low pH, which results in
the rescue of molecules from developing lysosomes. The receptor
then transports its cargo to either the apical or basolateral surface,
and releases it at neutral pH, thereby accomplishing transcytosis
or recycling. In this way, FcRn is apparently able to transport IgG
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effectively, even through stratified cell layers as for example in the
placenta [reviewed in (69)], and perhaps also through walls of
vaginal and oral cavities, although this has not been proven. How-
ever, the FcRn is not only expressed on epithelial and endothelial
cells, but also at high levels on myeloid cells where it participates
in phagocytosis of IgG-opsonized bacteria and immune complex-
uptake (70) and can enhance antigen presentation on dendritic
cells (DCs) (71–77). It has also been reported to be responsi-
ble for bidirectional transport of IgG across epithelial layers and
to play a vital role in delivery of IgG to the lumen of the gut,
genital areas, and lung (73, 74, 78) (Figure 1B). In this way,
FcRn has for example been shown to bring protective immu-
nity against helicobacter species (79). Inflammation caused by
such infection, may affect FcRn expression, as FcRn is sensitive
to NFκB-signaling. In accordance, FcRn expression is upregulated
by TNF-α, but also by the TLR ligands gram negative endotox-
ins (lipopolysaccharides) and CpG oligodeoxynucleotides (80).
This may not only cause increase in the FcRn-saturation levels,
causing increase in systemic IgG and albumin levels (64, 81), but
also increased transport of locally and/or systematically produced
IgG and albumin, and perhaps explain increased mucosal trans-
port of IgG in pIgR KO mice that display increased IgG and
albumin levels (82). The increased salivary IgG levels found for
example in excessive Gingivitis cases, may therefore very well due
to FcRn-upregulation, but it still need to be tested whether this is
the case, as inflammation may also cause excessive leakiness of the
epithelium (83).
In addition to IgG catabolism and transfer, the FcRn may
mediate transport of IgG-antigen complexes from the basolat-
eral surface back to the intestinal lumen. In this way FcRn has
also been demonstrated to actively participate in the intracel-
lular viral neutralization (84). Perhaps even more importantly,
this transport is bidirectional as FcRn can mediate antigen sam-
pling by transporting these IgG-antigen complexes from the lumen
to regional lymphoid structures for amplification of immune
responses (74) (Figure 3). The IgG response generated in this
FIGURE 3 | Antigen sampling and amplification of humoral immune
responses. (A) SIgA recognizing its cognate antigen (1) is taken up by M cell,
possibly though a yet unidentified receptor on M cells. This complex has been
demonstrated to traverse the epithelial layer (2) and to be taken up by DCs (3)
possibly through DC-SIGN recognition. (B) Similarly, antigen bound by IgG (1)
can traverse the epithelial layer through FcRn-depended transcytosis and
taken up by DCs through FcγR and FcRn (2) (73). Both IgG- or IgA-mediated
antigen uptake can enhance antigen presentation, subsequent activation and
proliferation of antigen-specific B- and T cells, boosting immune responses
(3). See text for more details.
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way further stimulates secretion of immunoglobulin and its trans-
port to the lumen where it actively mediates clearance and/or
protection against pathogens, as recently shown for immunity
against HIV and Citrobacter rodentium in a mouse models (74,
85, 86). FcRn is therefore active at various levels in immunity;
from half-life extension of IgG to transport of IgG to relevant
sites, and together with classical FcγR, directs pathogen eradica-
tion by phagocytosis and amplification of immune responses (70,
73–77, 85).
In rodent models, FcRn also has a potentially important role
in transmission of IgG from the breast milk of allergic mothers
which has been shown to decrease the severity of allergic dis-
ease in the suckling offspring (87–89). This pathway is probably
limited to species where materno-fetal transfer of IgG takes place
through breastfeeding, and is thus not applicable to humans where
IgG is almost exclusively transferred to the neonate before birth
via the placenta. However, it is as of yet unknown if placental-
transport of IgG may affect sensitization of the newborn to
allergens.
LESS CHARACTERIZED Ig-RECEPTORS
Numerous other receptors have been described to bind
immunoglobulins (Table 1), but many need confirmation, while
the function of many others is completely unknown. An example
is the FcεRII (CD23), which has been described to translocate
IgE bilaterally through gut epithelial cells, capable of translo-
cating IgE-bound allergens, perhaps explaining some aspects of
food allergy, but also immunity against gut parasites (90, 91).
One intriguing scenario is the possible role for SIgA in immune
surveillance by the sampling of antigens from the lumen of the
intestine. By transcytosis through M cells of the Peyer’s patches on
its own or in complex with antigen, IgA has been found to inter-
act with sub-epithelial DCs. The receptor on M cells is hitherto
unreported but interactions with DCs are believed to be medi-
ated by DC-SIGN (Figure 3A) (92). Curiously, DC-SIGN has
also recently been described to bind Fc-sialylated IgG (93, 94),
a subfraction of IgG, representing approximately 10% of all IgG.
Although the interaction between sialylated IgG and DC-SIGN
in this case was found to have immunomodulatory properties
(given as IVIg in rodent models), up regulating the inhibitory
FcγRIIb in the myeloid compartment, the normal physiological
role of this interaction between Ig and DC-SIGN is still com-
pletely unknown. Curiously, DC-SIGN is encoded in a cluster of
related genes, which includes CD23, which, like DC-SIGN, is a
type II trimeric membrane lectin. The C terminal domain of these
proteins, in CD23 encoding for the binding domain for IgE – to
which it binds through protein–protein interaction (95) – share
42% sequence homology, and are structurally highly conserved
(structural alignment of DC-SIGN PDB ID 1K9J vs. CD23 PDB
ID 4EZM). Furthermore, the location in where CD23 interacts
with IgE, is highly homologous to CH2/CH3 of the IgG-Fc, sug-
gesting that DC-SIGN may perhaps also interact with IgG through
protein–protein interactions (96), which would explain why a
recent study found no indication of DC-SIGN interacting with
glycan structures of IgG (97). An even more curious receptor, the
Tripartite Motif-containing 21 (TRIM21) is expressed in the cyto-
plasm of most cells, particularly in immune cell, and recognizes at
least both IgG and IgM (98, 99). The binding to IgG is of very high
(K d= 37 nM), requires the TRIM21 PRYSPRY motif, and binds
IgG in the interface of CH2 and CH3, to a similar same inter-
face as protein A/G and FcRn (99, 100). The peculiar cytoplasmic
location of TRIM21 renders it physically incapable of interact-
ing with immunoglobulin under normal circumstances. However,
TRIM is apparently capable of recognizing opsonized viral targets
after internalization and cytoplasmic translocation and inhibits
their cytoplasmic replication by targeting them for ubiquitination-
dependent destruction (99). Importantly, this would only tar-
get non-enveloped viral particles like noroviruses, rotaviruses, or
human papilloma viruses, but not enveloped viruses, as these
shed their opsonized envelopes on cytoplasmic entry. Recently,
James and colleagues describe TRIM21 to recognize other iso-
types as well, like IgM, and triggering a surge of proinflammatory
cytokines, also in response to Ig-opsonized intracellular bacteria
like Salmonella (101). It is unclear how the relative importance
of this pathway in host-protect is, given that systemic elimina-
tion by other pathways (e.g., complement, FcγR, and myeloid
system). The current evidence therefore suggest TRIM21 to be
particularly important at locations where complement and the
myeloid system are less prominently present, e.g., at mucosal sur-
faces of the gut. The relative importance of this system compared
to the other receptor systems for viral elimination awaits further
confirmation.
CONCLUSION
Recent advances in knowledge of mucosal antibodies and novel
receptor functions, provides a platform for work toward the induc-
tion of protective mucosal immune responses. Considerably fur-
ther research into the precise mechanisms involved are required in
order to understand how to elicit protective immune responses
required for both systemic and mucosal protection, informa-
tion that will also benefit passively administered immunoglobulin
therapies.
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